Compare AbCellera Biologics Inc (ABCL) vs Electronic Arts Inc. (EA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Electronic Arts Inc. — how do they compare? AbCellera Biologics Inc trades at $7.24 (market cap $2.35B), while Electronic Arts Inc. trades at $205.35 (market cap $51.51B). The key difference: Electronic Arts Inc. is far larger — about 21.9× AbCellera Biologics Inc's market cap, and Electronic Arts Inc. pays a 0.37% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EA | |
|---|---|---|
Market Cap | $2.35B | $51.51B |
Sector | Health | Technology |
52-Week High | $8.12 | $205.45 |
52-Week Low | $2.78 | $147.79 |
Enterprise Value | $1.99B | $50.08B |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Electronic Arts (EA) trades at $205.44, up 0.11% on the day, with a bullish technical signal from moving averages and strong profitability metrics including a 78.97% gross margin. Recent news highlights a potential $55 billion acquisition by Saudi investors pending EU approval and the launch of new gaming titles and an advertising platform, indicating active business development.
The stock presents a mixed outlook with high valuation ratios (P/E of 58.46) posing a risk, but analyst consensus leans positive with no sell ratings. Key risks include earnings volatility, as seen in recent misses, and regulatory scrutiny over the acquisition. Upside potential hinges on successful game launches and the advertising initiative driving future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →
